Plazmaferézis és kombinált immunmoduláns terápia hatása súlyos tünetekkel járó Guillain-Barré-szindrómás betegek kórlefolyására.

Translated title of the contribution: The effect of plasmapheresis and other immunomodulating therapies on the course of severe Guillain-Barré syndrome

E. Hidasi, P. Soltész

Research output: Contribution to journalArticle

Abstract

Clinical datas of 20 patients with severe Guillain-Barre syndrome were evaluated retrospectively. The diagnosis was established on the electrophysiological and histopathological examinations (electroneurography, electromyography, sural nerve and muscle biopsy) and the analysis of the cerebrospinal fluid. All of the patients were treated with plasma exchange and some of them with other immunomodulant therapies (intravenous immunoglobuline, steroid, cyclophosphamide), too. To judge the clinical state correctly we used the modified Rankin scale. The patient's follow up went on for maximum 4 years. The improvement was satisfactory in 7 cases (35%) and good in 6 patients (30%). The last 6 patients had pure motor neuropathy. Six patients (30%) remained in severe residual condition. All of them had long-term course of disease, serious sensory symptoms and predominantly axonal degeneration of the peripheral nerves. One patient had died. The plasma exchanges were well tolerated, without any serious adverse event. This therapy would be safe and effective help in Guillain-Barre syndrome.

Original languageHungarian
Pages (from-to)335-339
Number of pages5
JournalOrvosi Hetilap
Volume142
Issue number7
Publication statusPublished - Feb 18 2001

Fingerprint

Plasmapheresis
Plasma Exchange
Guillain-Barre Syndrome
Therapeutics
Sural Nerve
Electromyography
Peripheral Nerves
Cyclophosphamide
Cerebrospinal Fluid
Steroids
Biopsy
Muscles

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{560bef0bd29d44939b346a76fbcb5643,
title = "Plazmafer{\'e}zis {\'e}s kombin{\'a}lt immunmodul{\'a}ns ter{\'a}pia hat{\'a}sa s{\'u}lyos t{\"u}netekkel j{\'a}r{\'o} Guillain-Barr{\'e}-szindr{\'o}m{\'a}s betegek k{\'o}rlefoly{\'a}s{\'a}ra.",
abstract = "Clinical datas of 20 patients with severe Guillain-Barre syndrome were evaluated retrospectively. The diagnosis was established on the electrophysiological and histopathological examinations (electroneurography, electromyography, sural nerve and muscle biopsy) and the analysis of the cerebrospinal fluid. All of the patients were treated with plasma exchange and some of them with other immunomodulant therapies (intravenous immunoglobuline, steroid, cyclophosphamide), too. To judge the clinical state correctly we used the modified Rankin scale. The patient's follow up went on for maximum 4 years. The improvement was satisfactory in 7 cases (35{\%}) and good in 6 patients (30{\%}). The last 6 patients had pure motor neuropathy. Six patients (30{\%}) remained in severe residual condition. All of them had long-term course of disease, serious sensory symptoms and predominantly axonal degeneration of the peripheral nerves. One patient had died. The plasma exchanges were well tolerated, without any serious adverse event. This therapy would be safe and effective help in Guillain-Barre syndrome.",
author = "E. Hidasi and P. Solt{\'e}sz",
year = "2001",
month = "2",
day = "18",
language = "Hungarian",
volume = "142",
pages = "335--339",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "7",

}

TY - JOUR

T1 - Plazmaferézis és kombinált immunmoduláns terápia hatása súlyos tünetekkel járó Guillain-Barré-szindrómás betegek kórlefolyására.

AU - Hidasi, E.

AU - Soltész, P.

PY - 2001/2/18

Y1 - 2001/2/18

N2 - Clinical datas of 20 patients with severe Guillain-Barre syndrome were evaluated retrospectively. The diagnosis was established on the electrophysiological and histopathological examinations (electroneurography, electromyography, sural nerve and muscle biopsy) and the analysis of the cerebrospinal fluid. All of the patients were treated with plasma exchange and some of them with other immunomodulant therapies (intravenous immunoglobuline, steroid, cyclophosphamide), too. To judge the clinical state correctly we used the modified Rankin scale. The patient's follow up went on for maximum 4 years. The improvement was satisfactory in 7 cases (35%) and good in 6 patients (30%). The last 6 patients had pure motor neuropathy. Six patients (30%) remained in severe residual condition. All of them had long-term course of disease, serious sensory symptoms and predominantly axonal degeneration of the peripheral nerves. One patient had died. The plasma exchanges were well tolerated, without any serious adverse event. This therapy would be safe and effective help in Guillain-Barre syndrome.

AB - Clinical datas of 20 patients with severe Guillain-Barre syndrome were evaluated retrospectively. The diagnosis was established on the electrophysiological and histopathological examinations (electroneurography, electromyography, sural nerve and muscle biopsy) and the analysis of the cerebrospinal fluid. All of the patients were treated with plasma exchange and some of them with other immunomodulant therapies (intravenous immunoglobuline, steroid, cyclophosphamide), too. To judge the clinical state correctly we used the modified Rankin scale. The patient's follow up went on for maximum 4 years. The improvement was satisfactory in 7 cases (35%) and good in 6 patients (30%). The last 6 patients had pure motor neuropathy. Six patients (30%) remained in severe residual condition. All of them had long-term course of disease, serious sensory symptoms and predominantly axonal degeneration of the peripheral nerves. One patient had died. The plasma exchanges were well tolerated, without any serious adverse event. This therapy would be safe and effective help in Guillain-Barre syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0035906036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035906036&partnerID=8YFLogxK

M3 - Article

C2 - 11243015

AN - SCOPUS:0035906036

VL - 142

SP - 335

EP - 339

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 7

ER -